BR9106601A - Adjustante de vacina e processo de obter aumento da resposta imunologica a um antigeno em um ser humano ou animal - Google Patents

Adjustante de vacina e processo de obter aumento da resposta imunologica a um antigeno em um ser humano ou animal

Info

Publication number
BR9106601A
BR9106601A BR919106601A BR9106601A BR9106601A BR 9106601 A BR9106601 A BR 9106601A BR 919106601 A BR919106601 A BR 919106601A BR 9106601 A BR9106601 A BR 9106601A BR 9106601 A BR9106601 A BR 9106601A
Authority
BR
Brazil
Prior art keywords
antigen
isotype
present
animal
human
Prior art date
Application number
BR919106601A
Other languages
English (en)
Inventor
Robert L Hunter
Kuni K Takayama
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BR9106601A publication Critical patent/BR9106601A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR919106601A 1990-06-27 1991-06-27 Adjustante de vacina e processo de obter aumento da resposta imunologica a um antigeno em um ser humano ou animal BR9106601A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54483190A 1990-06-27 1990-06-27
US71680791A 1991-06-21 1991-06-21
PCT/US1991/004716 WO1992000101A1 (en) 1990-06-27 1991-06-27 Improved adjuvants and vaccines

Publications (1)

Publication Number Publication Date
BR9106601A true BR9106601A (pt) 1993-04-20

Family

ID=27067746

Family Applications (1)

Application Number Title Priority Date Filing Date
BR919106601A BR9106601A (pt) 1990-06-27 1991-06-27 Adjustante de vacina e processo de obter aumento da resposta imunologica a um antigeno em um ser humano ou animal

Country Status (17)

Country Link
EP (1) EP0536302B1 (pt)
JP (1) JPH0832639B2 (pt)
KR (1) KR100218138B1 (pt)
CN (1) CN1060027A (pt)
AT (1) ATE157259T1 (pt)
AU (1) AU655593B2 (pt)
BR (1) BR9106601A (pt)
CA (1) CA2086097C (pt)
DE (1) DE69127445T2 (pt)
DK (1) DK0536302T3 (pt)
ES (1) ES2104712T3 (pt)
GR (1) GR3025341T3 (pt)
IE (1) IE912257A1 (pt)
IL (1) IL98655A0 (pt)
NZ (1) NZ238731A (pt)
PT (1) PT98119B (pt)
WO (1) WO1992000101A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3723231B2 (ja) * 1991-12-23 2005-12-07 ディミナコ アクチェンゲゼルシャフト アジュバント
US6153193A (en) * 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6277410B1 (en) * 1992-10-08 2001-08-21 Supratek Pharma Inc. Copolymer compositions for oral delivery
US5407585A (en) * 1993-08-16 1995-04-18 Exxon Chemical Patents Inc. Method of demulsifying water-in-oil emulsions
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1181937A3 (en) * 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
AU6358898A (en) * 1996-09-09 1998-04-17 Alexander V Kabanov Fluorinated copolymeric pharmaceutical adjuncts
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6368604B1 (en) 1997-09-26 2002-04-09 University Of Maryland Biotechnology Institute Non-pyrogenic derivatives of lipid A
US7297330B2 (en) * 2000-02-04 2007-11-20 Thomas Jefferson University Low dose haptenized tumor cell and tumor cell extract immunotherapy
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
CN102580081B (zh) * 2012-02-22 2014-07-02 中国医学科学院医学生物学研究所 Nad、氢氧化铝复合佐剂及含该复合佐剂的疫苗
CN113527417B (zh) * 2021-07-05 2022-09-27 中国医学科学院放射医学研究所 一种含氟基团的自组装多肽纳米佐剂及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380726D1 (en) * 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4770874A (en) * 1983-08-22 1988-09-13 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants

Also Published As

Publication number Publication date
AU655593B2 (en) 1995-01-05
CA2086097C (en) 2001-06-12
PT98119A (pt) 1992-04-30
PT98119B (pt) 1998-12-31
ES2104712T3 (es) 1997-10-16
AU8286191A (en) 1992-01-23
DE69127445D1 (de) 1997-10-02
WO1992000101A1 (en) 1992-01-09
CA2086097A1 (en) 1991-12-28
ATE157259T1 (de) 1997-09-15
CN1060027A (zh) 1992-04-08
NZ238731A (en) 1996-02-27
JPH05507498A (ja) 1993-10-28
EP0536302B1 (en) 1997-08-27
JPH0832639B2 (ja) 1996-03-29
KR100218138B1 (en) 1999-09-01
EP0536302A1 (en) 1993-04-14
DK0536302T3 (da) 1997-09-29
EP0536302A4 (en) 1993-08-04
IL98655A0 (en) 1992-07-15
GR3025341T3 (en) 1998-02-27
IE912257A1 (en) 1992-01-01
DE69127445T2 (de) 1998-03-19

Similar Documents

Publication Publication Date Title
BR9106601A (pt) Adjustante de vacina e processo de obter aumento da resposta imunologica a um antigeno em um ser humano ou animal
BR0007936A (pt) Composto, formulação adjuvante imunológica, formulação de vacina, e, processo para estimular uma resposta imune a um antìgeno
DE69332518D1 (de) Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
DE69331901D1 (de) Impfstoff auf urease-basis gegen helicobacter infektionen
NZ323973A (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
CA2264810A1 (en) Method of producing active immunity with vaccine conjugate
DK0755684T3 (da) Vaccinekonjugat
NO933856L (no) Pediatrisk kombinasjonsvaksine
EP0142345A3 (en) Anti-idiotypic vaccine employing anti-idiotypic monoclonal antibodies
Lemley et al. Mice are actively immunized after passive monoclonal antibody prophylaxis and ricin toxin challenge
DE69030099D1 (de) Verfahren zur herstellung von impfstoffen oder toxoiden
AU3478393A (en) Vaccine containing acemannan as an adjuvant
ATE234109T1 (de) Cetp zur erhöhung des hdl-cholesterol-gehalts
NO307815B1 (no) Levende eller inaktivert parental vaksine mot rotavirusinfeksjon
DE69322960D1 (de) Empfängnisverhütender impfstoff
Başalp et al. Enhancement of the immune response to hepatitis B virus vaccine by antigen specific IgM
DE69833568D1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
Kiseleva et al. Comparative study of the concentration of antibodies and protective activity to Pseudomonas aeruginosa in the preparations of gamma globulin and IgM-enriched immunoglobulin.
Abdeen Anti-Adult Worm Antibodies From Irradiated Cercariae-Immunized Rabbits Passively Transfer Immunity To Schistosoma haematobium-Infected Mice.
ELISA-IgG Rajesh K. Gupta, Carole L. Varanelli, Paul Griffin, Donald FH Wallah and George R. Siber.“Adjuvant properties of non-phospholipid liposomes (Novasomes@) in experimental animals for human vaccine antigens”. Vaccine 14 (3): 219-225, 1996.
Watanabe et al. Immunity in cholera
White An evaluation of immunoglobulin isotype expression in immunity to the rodent malarial parasite, Plasmodium Yoelii
XIE et al. Role of humoral immune response in the protection induced by H. pylori vaccine with chitosa as adjuvant
Dzheksenbaev et al. Role of the adenyl cyclase system in stimulation of immunogenesis by bacterial lipopolysaccharide and by endogenous serum pyrogen
MX9709851A (es) Epitopes neutralizadores conformacionales del virus de la anemia de pollo.

Legal Events

Date Code Title Description
FD3 Appl. lapsed due to non-payment of renewal fee
B15K Others concerning applications: alteration of classification

Ipc: A61K 39/39 (2006.01), A61K 39/00 (2006.0